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Abstract: The link between chronic immune activation and tumor-
igenesis is well established. Compelling evidence has accumulated
that histologic assessment of infiltration patterns of different host
immune response components in non-small cell lung cancer speci-
mens helps identify different prognostic patient subgroups. This
review provides an overview of recent insights gained in the under-
standing of the role played by chronic inflammation in lung carci-
nogenesis. The usefulness of quantification of different populations
of lymphocytes, natural killer cells, macrophages, and mast cells
within the tumor microenvironment in non-small cell lung cancer is
also discussed. In particular, the importance of assessment of in-
flammatory cell microlocalization within both the tumor islet and
surrounding stromal components is emphasized.
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There is now a general consensus that chronic inflam-mation plays a critical role in tumorigenesis.1 In re-
sponse to injury, there is activation of a complex integrated
system of mechanisms designed to eliminate the stimulus,
repair damaged tissue, and promote wound healing
through measured and organized cellular proliferation.
Under normal circumstances, this host physiological re-
sponse subsides once repair is completed. However, when
this usually tightly regulated self-limiting mechanism be-
comes disturbed, a state of chronic inflammation may
ensue.
Virchow2 first proposed the link between inflamma-
tion and neoplasia when he observed that cancer seemed to
develop at sites of previous chronic inflammation. The
initial suggestion that tumor-infiltrating lymphocytes
(TIL) may represent an expression of host antitumour
activity was supported by evidence linking TIL with im-
proved prognosis in solid cancers.3,4 Forty years later,
there is now a wealth of accumulated data to support the
hypothesis that organs affected by chronic inflammation
provide the perfect milieu in which an abnormal clone or
clones of cells are capable of evading detection by the host
immune system and progress to invasive carcinoma.
This review summarizes recent insights gained in the
understanding of the role played by chronic inflammation
in lung carcinogenesis. The usefulness of various methods
of quantification of different inflammatory cell populations
within the tumor microenvironment in non-small cell lung
cancer (NSCLC) using immunohistochemistry is dis-
cussed. In particular, the importance of assessment of
inflammatory cell microlocalization within both the tumor
islet and surrounding stromal components is emphasized.
CHRONIC IMMUNE ACTIVATION AND
CARCINOGENESIS
The adaptive immune response is known to comprise
two essential and complementary components: cell-medi-
ated immunity (CMI) and humoral immunity (HI). The
CD4 T-helper (TH) lymphocyte is an essential element of
both systems and is responsible for orchestrating two
different but overlapping cytokine patterns that influence
other effector cells and in turn shape the pattern of the
inflammatory response.5
The molecular mechanisms that underlie the evolu-
tion of matured naive (TH0) CD4
 cells into distinct
populations that are characterized by either a CMI or HI
phenotype are still not completely understood. However,
the nature of the cytokine milieu in which antigen presen-
tation occurs influences the differentiation of TH0 cells.
Early production of interleukin (IL)-12 by mature dendritic
cells stimulates upregulation of CMI by effector/memory
cells and is characterized by the production of the TH1
cytokines IL-2, interferon (IFN)-, and tumor necrosis
factor (TNF)-.6 These cytokines exert antiangiogenic and
proapoptotic effects. By contrast, HI is characterized by
the production of proangiogenic, antiapoptotic TH2 cyto-
kines such as IL-4, IL-5, IL-6, IL-10, and IL-13.7 Immune
deviation toward a dominant TH1 response facilitates can-
cer cell killing and tumor rejection.8 Conversely, a domi-
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nant TH2 response may be regarded as favorable for tumor
progression.9
Under prevailing physiological conditions, a delicate
balance exists between CMI and HI responses. In response
to an inflammatory stimulus (e.g., exposure to a viral
pathogen), there is activation of both systems to clear the
injurious stimulus. Once the offending pathogen is suc-
cessfully removed, and in order for effective wound heal-
ing to occur, there is a relative reduction in CMI and
upregulation of HI.10 Thereafter, the normal balance be-
tween CMI and HI is reestablished. However, in circum-
stances where the host is unable to effectively remove the
inciting stimulus, the inflammatory cellular components
persist and a chronic inflammatory response may develop.
Such a pattern is characteristic of a number of human
infectious diseases such as Epstein-Barr virus, human
papillomavirus, hepatitis B and C, human immunodefi-
ciency virus/acquired immunodeficiency syndrome, Heli-
cobacter pylori, and schistosomiasis.11 A failure of host
infection-clearing mechanisms is typical of each of these
chronic infections.
Several lines of evidence indicate that many cancers
develop in the setting of such chronic immune activation.
In these circumstances, there is not only an overall up-
regulation of immune responses but a shift in the immune
response to one that is characterized by a wound healing,
proangiogenic, antiapoptotic cytokine pattern. As the ma-
lignant process develops, cancer cells evolve to subvert the
CMI response. Taken together, these findings highlight the
critical role played by the immune system in determining
outcome with respect to tumorigenesis.10,11
THE ROLE OF CHRONIC INFLAMMATION IN
LUNG CANCER PATHOGENESIS
Cigarette Smoking
Cigarette smoking is established as the leading risk
factor for lung cancer, and the overwhelming majority of
patients diagnosed with the disease are current or former
smokers. There is increasing evidence that tobacco smoke
exposure promotes widespread inflammatory and muta-
genic effects in the lungs that promote a pro-cancer im-
mune response. Indeed, the initial pathologic hallmark of
smoking is a widespread inflammatory infiltrate through-
out the lung parenchyma.12 Repeated injury to lung epi-
thelial cells caused by inhalation of noxious particulate
matter from cigarette smoke drives ongoing recruitment of
host inflammatory cells to lung airways and alveolar tissue.
The lungs of smokers are characterized by increased num-
bers and enhanced activation of macrophages, dendritic
cells, activated lymphocytes, and granulocytes, thereby
producing an environment conducive to the proliferation
of malignantly transformed cells.
Environmental Tobacco Smoke
Environmental tobacco smoke (ETS), also referred to
as “passive” or “involuntary” smoking, has been exten-
sively investigated as a potential cause of lung cancer. The
National Research Council in the United States estimates
that 2 to 3% of all lung cancer (about 3000 cases per year)
may be attributable to ETS. Much of epidemiologic re-
search on ETS has examined the relative risk increase
among nonsmoking women according to the level of smok-
ing by husbands. Overall, there is an increased risk of at
least 20% among nonsmoking wives of smoking husbands
when compared with nonsmoking wives of nonsmoking
husbands.14 Prolonged exposure to ETS in the workplace
also confers an increased risk and forms the basis for
smoking ban legislation in an increasing number of coun-
tries.
Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a dis-
order characterized by an abnormal local and systemic inflam-
matory response and is strongly associated with lung cancer.15,16
Within the lung, cigarette smoke incites a potent inflammatory
reaction in the airways and alveoli of susceptible smokers, a
process etiologically important in driving both proteolytic alve-
olar destruction and airway remodeling, the pathologic hall-
marks of COPD.17 The inflammatory responses that characterize
COPD drive a repetitive cycle of injury and repair throughout
the lungs. These persistent biologic effects also increase the risk
of transformation of normal bronchial epithelium to a malignant
phenotype.
There are data confirming that reduction in lung
function, the physiologic hallmark of COPD, is associated
with increased markers of systemic inflammation. In par-
ticular, levels of forced expiratory volume in one second
(FEV1) show an inverse correlation with levels of C-reac-
tive protein, a sensitive marker of inflammation.18 Numer-
ous epidemiological studies have evaluated the relation-
ship between lung cancer and abnormalities of pulmonary
function, with moderate to severe airflow obstruction now
recognized as an independent predictor of incident lung
cancer.19 This risk increases with worsening severity of
lung function impairment as measured by FEV1 and ap-
pears particularly strong in women.20
Nonsmoking-Related Factors
Exposure to tobacco smoke is indisputably the most
important risk factor for the development of both COPD
and lung cancer in susceptible hosts. However, approxi-
mately 10% of lung cancers occur in lifelong nonsmokers,
indicating that other factors must be etiologically relevant
in lung carcinogenesis.21 In this regard, a number of other
disorders of the respiratory system in which inflammation
is pathogenic, both infectious and noninfectious, have been
linked to the development of lung cancer.
Pulmonary Infections
Much of the evidence for the increased risk of lung
cancer in the setting of prior infection due to Mycobacte-
rium tuberculosis has been derived from large epidemio-
logical studies. A large population-based case-control
study conducted in China among individuals with evidence
of previous tuberculosis disease showed a positive corre-
lation with both adenocarcinoma and squamous cell cancer
subtypes, which was independent of smoking status and
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socioeconomic group.22 Zheng et al.23 reported that a prior
diagnosis of tuberculosis increased the risk of lung cancer
by approximately 50%, with the effect most apparent
among those with recent infection.
A causal association between lung cancer and Chla-
mydia pneumonia has been the subject of investigation24
using serologic testing as evidence of prior infection. The
precise mechanisms to explain this epidemiological link
remain poorly understood. Chronic infection with C. pneu-
monia has been shown to result in impaired apoptosis of
infected cells by induction of the key immunosuppressive
cytokine IL-10 resulting in reduced antitumor CMI re-
sponses.25 Another postulated mechanism by which C.
pneumonia may increase risk of malignancy is through
upregulation of IL-8 and promotion of angiogenesis and
cellular proliferation.26
Occupational Dust Exposure
Accumulated epidemiological data have suggested
that fibrotic lung diseases may also predispose to lung
tumorigenesis. This link was initially suggested by the
finding of coexisting interstitial lung disease and lung
carcinoma in autopsy studies.27 The observed increased
incidence of lung cancer in follow-up studies of workers
exposed to asbestos and silica seems to support this hy-
pothesis.28,29
The link between asbestos and lung cancer was first
made nearly 70 years ago, an association that was strength-
ened by epidemiologic data from the 1960s showing that
textile workers in Britain exposed to high levels of asbestos
dust had a 10-fold increased incidence.30 The risk conferred
by asbestos exposure is increased in a multiplicative manner
in smokers because of a synergistic effect of several carcin-
ogens found in cigarette smoke. Results from a European
collaborative study confirmed the association between occu-
pational crystalline silica dust exposure and lung cancer, with
a twofold increased risk observed among individuals with
greatest exposure.31 Other proven or suspected occupational
risk factors include nickel, chromium, beryllium, arsenic, and
silica.
Idiopathic Pulmonary Fibrosis
A study examining a cohort of patients with idio-
pathic pulmonary fibrosis found that the incidence of lung
cancer was increased sevenfold compared with controls.32
This increased risk was independent of cigarette smoking
history. It has been suggested that overexpression and
subsequent mutation of the p53 gene that occur with
inflammation/fibrosis-associated oxidative DNA damage
and repair may contribute to the emergence of a pro-tumor
environment in patients with idiopathic pulmonary fibro-
sis.33
Experimental Models
Animal experiments have provided additional impor-
tant evidence of the potential contribution of immune
activation to lung carcinogenesis in the context of expo-
sure to inorganic dusts. Using a mouse model, Saffiotti and
coworkers showed that intratracheal instillation of chemi-
cal particles evokes a potent inflammatory response that
eventually leads to the development of NSCLC.34 Insuf-
flation of particulate silica, a potent lung irritant, causes a
brisk granulomatous reaction in the murine bronchial tree.
Recruitment of inflammatory cells to affected airways
predictably leads to hyperplasia of affected bronchiolar
epithelium and type 2 pneumocytes. Subsequently, the
mouse lung characteristically undergoes progressive
changes through hyperplasia to adenoma formation and,
ultimately, carcinoma. Whether or not a similar mecha-
nism accounts for lung cancer development in humans
remains to be clarified.
Cyclooxygenase
In recent years, attention has been drawn to the
pathogenic role played by the prostaglandins and their
upstream regulators of production, the cyclooxygenases
(COXs), in the progression of malignant disease.35 COX
consists of two distinct isoforms, COX-1 and COX-2;
COX-1 is constitutively expressed and regulates a number
of physiological functions, and production of the early
response gene COX-2 is induced in response to inflamma-
tory stimuli through the action of various cytokines and
growth factors. However, tumor promoters also upregulate
COX-2 synthesis, and many of the fundamental compo-
nents of carcinogenesis and cancer development are known
to be mediated via its actions. These include impairment of
CMI, apoptosis resistance, cellular proliferation, enhanced
angiogenesis, increased invasion, and metastasis.36
Increased levels of COX has been demonstrated in the
initiation stage of a variety of cancers.37 Epidemiological
evidence indicates that long-term users of nonsteroidal anti-
inflammatory drugs (agents that block the proinflammatory
effects of COX) have an approximate 50% reduction in risk
of colon cancer and may confer reduced risk of lung, esoph-
agus, and gastric cancer.38,39 Several investigators have con-
firmed that both NSCLC and associated precursor lesions
(adenomatous hyperplasia and carcinoma in situ) are associ-
ated with COX-2 overexpression.40–42 Quantification of
COX-2 expression may add useful independent prognostic
information in resected NSCLC patients.43
EGFR and EML4-ALK Mutations
There is now compelling evidence of the importance
of both activating mutations within the EGFR44 and dif-
ferent variants of the EML4-ALK fusion gene45 in the
pathogenesis of lung cancer among never or former light
cigarette smokers. However, the potential etiological rel-
evance of host immune dysregulation with respect to lung
cancer among exclusively nonsmokers has not thus far
been specifically investigated. In addition, the nature of the
immune response in patients with these genetic mutations
in the context of lung cancer has yet to be established.
Given the heterogeneity of established risk factors already
discussed for lung cancer among nonsmokers, it is proba-
ble that lung carcinogenesis in this population is multifac-
torial. Furthermore, in light of the clear importance of
immune dysregulation for different forms of human cancer
that do not have as clear a link with smoking as does
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NSCLC (both as an initiating factor and as a determinant
of outcome for different stages of disease), it is likely that
aberrant immune responses play an important role in the
pathogenesis of disease even in those without significant
tobacco exposure. Additional clinical investigation to help
establish possible links between genetic mutations that are
more frequently observed in those with no or minimal
cigarette smoke exposure and immune dysregulation is
warranted.
RELATIONSHIP OF INFLAMMATORY CELL
INFILTRATE PATTERNS AND PROGNOSIS IN
NSCLC
From the earliest stages of cancer development, both
a systemic and locoregional inflammatory response is
induced in the host. The nature of this response is a critical
determinant of whether tumor growth is facilitated or
inhibited. Experimental evidence indicates that there is a
proliferation of host immune effector populations in re-
sponse to nascent tumors.6 It was previously believed that
this phenomenon represented a frustrated host antitumor
defense mechanism. However, there is now evidence that
the developing tumor is capable of adapting this host
immune response to create a microenvironment conducive
to its own survival and progression.46
There is conflicting evidence with regard to inflamma-
tory response patterns in lung cancer and their relationship to
survival, with evidence to support both beneficial and nega-
tive effects. As with other solid tumors, accumulating data
indicate that the nature of the both the innate and adaptive
immune responses to neoplastic challenge in the lung is of
critical importance. Early investigation suggested that an
enhanced lymphoreticular response conferred a survival ad-
vantage in lung cancer.47,48 However, variations in the num-
bers and clinical characteristics of patients analyzed in sub-
sequent studies, together with considerable heterogeneity in
the methods used to categorize and examine the inflammatory
cell infiltrate, have meant that a less than clear-cut relation-
ship with prognosis has emerged (Table 1). The specific
pattern of this response seems crucial in determining tumor
progression, and recent evidence suggests that precise local-
ization of immune cells within different parts of the tumor
influences phenotype.49
T-Lymphocytes
Abundant intratumoral infiltration by different T-
lymphocyte populations is a frequent observation in dif-
ferent forms of human cancers, and this histologic finding
has been linked to improved patient survival in numerous
studies.50–53 By contrast, other reports have suggested that
increased lymphocytic invasion in cancers predicts worse
outcome.54–56 However, it is clear that a failure of host
immune surveillance mechanisms, in which lymphocytes
play a pivotal role, is a key step in the early stages of tumor
development.
Although prominent T-lymphocyte infiltration is a
characteristic finding in many forms of malignancy, func-
tional aberrancy of these cells is often apparent. Several
processes may account for this anergy. Alterations of the
T-cell receptor (TCR) prevent effective recognition of the
major histocompatibility complex (MHC)-antigen complex
when T-lymphocytes encounter malignant cells. In addition,
decreased expression of signal transduction proteins, blunted
proliferative capabilities, and a change in cytokine expression
profile have also been observed.57 As distinct from normally
functioning circulating lymphocytes, TILs may respond in-
appropriately or not at all to conventional activating stimuli.58,59
Together, these effects result in impairment of effective
cancer cell killing mechanisms.
Tumor cell surface antigens and soluble products are
recognized and processed by host antigen-presenting cells
and result in the activation of specific CD4 helper T-
lymphocyte populations. The nature of the cytokine profile
elaborated by tumor cells influences whether the T-cell pop-
ulation that is expanded and recruited to the site of the tumor
is a dominant TH1 or TH2 pattern. For example, abundant
expression of the immunosuppressive cytokine transforming
growth factor (TGF)- promotes maturation of TH2 CD4

cells10 and also directly inhibits cytotoxic CD8 T-lympho-
cyte–mediated cancer killing mechanisms.60 Whether the
predominant prevailing immune pattern is the result of tumor
effects driven by surrounding stromal constituents or devel-
ops as a consequence of interplay between both elements
remains uncertain.46
There is increasing evidence that the immune system
recognizes and mounts a specific, albeit relatively ineffective,
antitumor response by recognizing cell surface-specific anti-
gens in NSCLC.1 The adaptive immune response, comprising
T-cells, B-cells and antibodies, has been the focus of exten-
sive research in lung cancer. Flow cytometric analyses have
demonstrated that the lymphocyte population within NSCLC
is characterized by a predominantly antitumor TH1 cytokine
phenotype.61 Furthermore, increased infiltration by CD3,
CD8, and B-type TILs shows a positive correlation with the
extent of tumor cell apoptosis using Terminal dUTP Nick
End Labeling (TUNEL) techniques to quantify fragmented
DNA segments. This relationship seems to be strongest with
higher grade tumors and is maintained even in patients with
advanced disease.62
Data from initial investigation of the prognostic
implication of TILs assessed overall counts irrespective of
location rather than classifying various infiltrating cell
types into different compartments with the tumor mass.63
Support for the notion that immune cell “microlocaliza-
tion” within lung tumors may be of greater relevance than
absolute numbers per se was provided by a study by
Johnson et al.64 These investigators found that grouping
patients defined by different levels of semiquantitatively
assessed chronic inflammatory cell infiltrate did not pro-
vide useful prognostic information. However, the identifi-
cation of high numbers of CD3 T-lymphocytes within
cancer islets as opposed to supporting peritumoral stroma
predicted a more favorable prognosis. Another study found
that determination of microlocalization infiltrative patterns
of CD8 lymphocytes did not seem to provide additional
prognostic information, although numbers evaluated in this
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TABLE 1. Studies Evaluating the Relationship Between Immune Cell Infiltrate and Prognosis in Non-small Cell Lung Cancer
Author
Study
Size
Immune Cell Subtype
Studied TNM Stage
Histological
Subtypes Key Findings
Lee et al.48 30 T lymphocytes, plasma
cells, neutrophils,
macrophages
III Sq, Ad, LC Increased stromal lymphocyte count associated
with improved survival
Tormanen-Napankangas
et al.62
84 CD3 and CD8 T
lymphocytes, B
lymphocytes,
macrophages
Not defined Sq, Ad, LC Increased intratumoral infiltration by CD3 and
CD8 T lymphocytes and B lymphocytes
associated with tumor cell apoptosis but not
prognosis
Johnson et al.64 95 CD3 and CD8 T
lymphocytes, B
lymphocytes, NK
cells, macrophages,
Langerhans cells
I–III Nonspecified NSCLC
(97%), SCLC (3%)
Improved prognosis in subgroup with higher
intratumoral infiltration of CD3 T
lymphocytes and S100 Langerhans cells
Trojan et al.65 31 CD8 T lymphocytes I–III Sq, Ad, LC No relationship between intratumoral lymphocyte
infiltration and prognosis
Kawai et al.66 199 CD8 T lymphocytes,
macrophages, mast
cells
IV Sq, Ad,
undifferentiated
NSCLC
Improved median survival times in patients with
high intratumoral macrophages and CD8 T
lymphocytes treated with adjuvant
chemotherapy
Al-Shibli et al.67 335 CD4 and CD8 T
lymphocytes, CD20
B lymphocytes
I–IIIA Sq, Ad, LC High intrastromal CD4 and CD8 lymphocyte
numbers an independent prognostic factor
Hiraoka et al.68 109 CD4 and CD8 T
lymphocytes
I–IIIA Sq, Ad, LC, AS,
carcinosarcomaa
High conjoint CD4 and CD8 T lymphocyte
stromal infiltration a favorable prognostic
factor
Wakabayashi et al.69 178 CD4 and CD8 T
lymphocytes
I–IIIA Sq, Ad Higher CD8 T lymphocyte intratumoral counts
associated with shorter 5-yr survival. Increased
intrastromal CD4 T lymphocyte counts a
favorable prognostic marker
Petersen et al.83 64 CD3 and Foxp3 T
lymphocytes
I Ad, Sq, “other” Higher risk of disease recurrence with high
intratumoral regulatory:total T-lymphocyte
ratio
Kerr et al.89 95 CD3 and CD8 T
lymphocytes, CD79
B lymphocytes, NK
cells, macrophages,
Langerhans cells
I–IIIb Sq, Ad, AS, LC,
SCLC, Car
Increased CD3 T lymphocytes, macrophages (in
tumor islets only) and CD4:CD8 ratio in
tumors showing histological appearances akin
to regressing malignant melanoma
Takanami et al.90 150 NK cells I–IIIA Ad NK cell infiltration (predominantly found in
stromal regions) a prognostic factor in
univariate analysis only
Villegas et al.91 50 NK cells I–IIIA Sq Low numbers of intratumoral NK cells associated
with increased risk of death
Welsh et al.49 175 Macrophages, mast cells I–IV Ad, Sq, “other” High tumor islet/stromal macrophage and tumor
islet/stromal mast ratios independent favorable
prognostic indicators
Ohri et al.101 40 Macrophages Sq, Ad, LC, “other” Tumor islets macrophages in patients with
increased 5-yr survival predominantly show a
cytotoxic M1 phenotype
Kim et al.102 144 Macrophages I–IV Sq, Ad, AS, LC High tumor islet macrophage count independent
predictor of improved 5-yr survival
Takanami et al.103 113 Macrophages I–IV Ad Greater macrophage infiltration associated with
increased microvessel density and worse
prognosis; macrophages predominantly
identified in stroma
Zeni et al.104 50 Macrophages I–IV Sq, Ad Increased IL-10 expression by tumor islet
macrophages associated with shorter survival
Imada et al.122 85 Mast cells I Sq, Ad Stromal mast cells correlate with angiogenesis
assessed by microvessel counts and poor
outcome
Tomita et al.125 90 Mast cells I–IV Ad Increased overall mast cell infiltration associated
with improved 5-yr survival rates postsurgery
a N  1.
b Four patients had undefined tumor, node, metastasis (TNM) stage.
Ad, adenocarcinoma; AS, adenosquamous; Car, carcinoid; CD, cluster of differentiation; IL, interleukin; LC, large cell carcinoma; M, macrophage; NK, natural killer; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer; Sq, squamous.
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study were small and immune populations were assessed in
a semiquantitative fashion.65
A principal antitumour host immunomechanism is
direct cytotoxicity of CD8 T-lymphocytes via the recog-
nition of tumor-associated antigens presented on MHC
class I molecules. The degree of CD8 T-lymphocyte
infiltration within cancer nests alone has variously
emerged as a positive,66,67 neutral,64,68 or negative69 prog-
nostic marker in previous studies. However, different
methods have been used to quantify the lymphoid infil-
trates in NSCLC specimens. While some studies have used
randomly selected regions for analyzing cell counts, others
have focused on those regions that have the highest counts
of lymphocytes within regions of tumor epithelium and
stroma. This introduces a potential regional analysis bias
that might account for some of the discrepancy of pub-
lished results. Furthermore, tumor specimens from some of
these studies were collected before the advent of newer,
more sophisticated staging technology such as computed
tomography and positron emission tomography imaging
modalities. Thus, while patients from previous studies may
have been regarded as having early-stage disease that was
amenable to surgical resection, undetected metastatic dis-
ease may have accounted for some of the differences in
outcome and acted as a potential confounder.
Aggregation of different cell types into tumor islets
may play an important role in the activation of cytotoxic
pathways. Concomitant infiltration by CD8 and CD4 TILs
seems an indicator of favorable prognosis, suggesting that
cellular cooperation between different lymphocyte subsets
may be necessary for effective tumor cell killing.68 In this
regard, CD4 T-cells seem to augment tumor cell antigenic-
ity and susceptibility to lysis by CD8 TILs via local release
of TNF- and IFN-.70 Similarly, synergy between TILs and
tumor associated macrophages (TAMs) may be required for
optimum antitumor activity, because a combined high tumor/
islet CD8 count ratio and high tumor/islet macrophage
count ratio confer a prognostic advantage.66
Several factors have been implicated in the relative
lymphocyte anergy that results in impaired T-cell mediated
cytotoxicity in lung cancer patients with high numbers of
TILs and poor outcomes. Although there is frequently exten-
sive infiltration of CD8 TILs within tumor nests, it seems
that it is mainly the peritumorally located CD8 cells that are
immunologically active as determined by measurement of
IFN- expression.65 By comparison, intratumoral effector
TILs are inadequately activated and display blunted cytotoxic
activity, in turn facilitating cancer progression.
There is increasing evidence to support the hypothesis
that NSCLC cells themselves induce a local and systemic HI
environment with a predominant TH2 cytokine pattern.10 A
host of human tumors, including NSCLC, are characterized
by overexpression of COX-2 which controls production of
different prostaglandin isoforms. The enzyme PGE2 stimu-
lates production of CD4 TH2 cells but is a potent inhibitor
of TH1 CD4
 T-cells. Experiments using both cell lines and
resected tissue specimens have confirmed that lung cancer
cells fail to express the TH1 cytokines IL-2 and IFN-,
whereas elaboration of IL-10 is significantly enhanced in
response to stimulation with IL-4 and TNF-.71 Furthermore,
increased serum concentrations of IL-10 predict reduced
survival in advanced NSCLC.72
The local elaboration of various immunosuppressive
cytokines, including IL-10, either from tumor cells them-
selves or from bordering stromal constituents, may hamper
effective cytotoxic mechanisms.73 Alterations in the TCR,
loss of signal transducing proteins, and/or attenuated co-
stimulatory signals from antigen-presenting cells have all
been suggested as contributory factors to account for this
anergy.74 Infiltrating TILs are known to demonstrate signifi-
cantly reduced expression of MHC class II molecules such as
HLA-DR 39,75 whereas cancer cells display reduced expres-
sion of class I MHC molecules.76 Effective cytotoxicity may
also be further inhibited by overproduction of various immu-
nosuppressive factors such as TGF- by lung cancer cells
despite a predominant CMI response.77
Further contributing to a milieu of immune tolerance,
accumulation of CD4CD25 regulatory T cells (Tregs) into
the tumor bed of NSCLC is a frequently observed histopatho-
logical phenomenon. This population of lymphocytes func-
tion to maintain peripheral tolerance via suppression of self-
antigen–reactive T-cells. Human Tregs coexpress the CD25
antigen and are identified by the presence of the intracellular
marker forkhead box P3 (Foxp3), a transcriptional repressor
required for maturation and immunosuppressive functional-
ity.78 It has been suggested that intratumoral accumulation of
Tregs may result in downregulation of T-cells reactive
against tumor antigens, thereby creating a more favorable
microenvironment for clonal tumor cell expansion. This hy-
pothesis is supported by experimental work by Willimsky et
al.,79 who used an experimental model of spontaneous tumor
development to show that Tregs suppress specific cytotoxic
antitumor elements.
As is the case in other cancers, increased levels of
Tregs in NSCLC correlate with tumor invasiveness and
metastatic potential. These cells express constitutively high
levels of cell surface CTLA-4, suggesting ongoing activation
of neighboring cells.80 Levels of intratumoral TGF- are
contributed by infiltrating Tregs, although directed inhibitory
effects by this population are maintained even in the absence
of this cytokine. Effective T-cell activation seems to be
specifically suppressed by Tregs through inhibition of IL-2,
which results in a selective inhibition of local host immune
responses.81
The expression of the immunosuppressive mediator
Foxp3 is, at least in part, regulated by tumor-derived COX-2,
which is constitutively overexpressed in lung cancer. Further-
more, COX-2 inhibition in vivo leads to impairment of Treg
function and reductions in the numbers of Foxp3-expressing
cells, promoting decreases in tumor size through restoration
of effectual host antitumour responses.82
To date, there have been relatively few studies that
have examined the clinical impact of intratumoral infiltration
by T-lymphocytes characterized by a regulatory phenotype in
the setting of lung cancer. Woo et al.74 found increased
amounts of tumor-associated CD4CD25 cells in NSCLC
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patients with early-stage disease compared with normal con-
trols. An immunosuppressive phenotype was further high-
lighted by the finding of spontaneous TGF- secretion among
TILs. Among patients with stage I NSCLC in this study,
increased intratumoral accumulation of Foxp3 Tregs rela-
tive to total TIL infiltration was associated with increased risk
of disease recurrence.83 However, assessment of Treg counts
in isolation did not yield prognostic information. These data
suggest that anticancer strategies that specifically target in-
tratumoral Tregs, either through a reduction in numbers or via
abrogation of immunosuppressive activity, may prove worthy
of future investigation.
Natural Killer Cells
Accumulated experimental data indicate that natural
killer (NK) cells display spontaneous cytotoxic activities
in the presence of cancer cells, suggesting an important
role in host defense against cancer progression. Cytotox-
icity mediated by tumor-infiltrating NK cells may be an
important determinant of outcome in NSCLC. In common
with other innate immune effectors, the antitumor activity
of NK cells is mediated independent of antigen-presenta-
tion mechanisms. Direct lysis of malignant cells that have
altered surface expression of MHC class I molecules
occurs in the context of release of perforin, a cytolytic
protein that inserts itself into the plasma membrane of the
target cell.84
There is evidence that patients exposed to cigarette
smoke, the commonest risk factor for the development of
NSCLC, have attenuated circulating NK cell activity.85 Sim-
ilarly, bronchoalveolar lavage sampling of smokers reveals
reduced NK functioning in comparison with nonsmokers.86
Although capable of direct tumor cell lysis in in vitro models,
there is emerging data that NK recognition and destruction of
tumor cells in NSCLC is impaired. Esendagli et al.87 recently
showed reduced numbers of NK cells within cancer tissue
compared with adjoining nonmalignant lung regions. Down-
regulated expression of several markers of NK activation
(e.g., NKG2D, NKp46, NKp30, and NKp44) may account for
the apparent reduced cytotoxicity within tumors. This finding
may help explain the attenuation of NK-mediated direct
cancer killing mechanisms. There is also emerging evidence
that dampening of NK cell-associated innate immune surveil-
lance is mediated in a TGF--dependent manner via cross-
talk with local Tregs.88
The prognostic relevance of host NK responses in
NSCLC has been the focus of attention in a number of
studies. Kerr et al.89 showed a marginal benefit among
postoperative cases with a high prevalence of NK tumor
infiltration. This association was confirmed in two studies
examining different histologic NSCLC subtypes. Taka-
nami et al.90 demonstrated a significant relationship be-
tween NK cell count and outcome in resected adenocarci-
noma, although NK cell infiltration was not an independent
prognostic factor in multivariate analysis. Villegas et al.91
demonstrated a positive correlation between postoperative
survival and numbers of intratumoral CD57 NK cells in
patients after resection of squamous cell cancer, particu-
larly in stage IB disease. Overall, the impact of NK cell
infiltration seems greatest in early-stage disease, suggest-
ing that as tumors progress, NK antitumor effector mech-
anisms become overwhelmed. Interestingly, an earlier
study examining a more heterogeneous patient cohort did
not identify any link between extent of NK cell infiltration
as assessed by cytofluorometry and outcome.63 However,
considerable methodological differences among these var-
ious studies may account for the divergence of results.
Furthermore, analysis of activation status of NK cells in
cancer islets shows increased expression of the inhibitory
receptor NKG2A, indicating an inactivated phenotype,
whereas their stromal counterparts are characterized by an
immune activated status.92 Thus, evaluation of the num-
bers of tumor-infiltrating NK cells in isolation may be
insufficient to generate prognostic information.
Co-operation between infiltrating NK and alveolar
macrophages may be necessary for effective killing of
transformed cells,93 yet simultaneous assessment for both
cell types has infrequently been carried out in pathologic
studies. The number of NK cells in direct contact with
cancer cells may also be an important consideration. With
respect to anatomic microlocalization, most NK cells re-
side within the peritumoral stroma and are not in direct
contact with cancer cells.94 This finding further highlights
the importance of detailed characterization of immune
effector populations and may help explain the functional
aberrancy of NK cells in the malignant environment.95
Macrophages
Macrophages are ubiquitous immune cells that direct
a number of vital physiological and host defense processes,
including pathogen phagocytosis, regulation of inflamma-
tion, and tissue repair. TAMs comprise a major constituent
of the leukocyte infiltrate characteristic of malignant dis-
ease and are present in abundance in both primary and
metastatic lesions. Within tumors, TAMs interact with
cancer cells to produce a rich source of cytokines and
growth factors that shape the local microenvironment.96
In recent years, a wealth of evidence has emerged
supporting the contention that macrophages play a key role
in tumor progression by facilitating cancer cell prolifera-
tion, migration and metastasis, stimulating angiogenesis,
and suppressing host antitumor immunity. Nevertheless,
there is considerable debate regarding the prognostic rel-
evance of TAMs in NSCLC.96,97 Although some investi-
gators have shown that increased number of TAMs confer
a survival advantage, others have identified this pattern as
a marker of poor outcome. This discrepancy is almost
certainly related to differences in numbers evaluated, tu-
mor stage, histology, size, and grade as well as the wide
variation in techniques used to analyze patterns of macro-
phage infiltration. However, perhaps most crucially, re-
searchers have often not taken the microanatomical local-
ization into consideration.98,99
The importance of accurate assessment of regional
infiltrative patterns was highlighted in a study that dem-
onstrated that microanatomical distribution of macro-
phages in resected NSCLC specimens exerts a powerful
impact on survival.49 Specifically, macrophage infiltration
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of tumor cell islets was shown to confer a marked survival
advantage, whereas stromal macrophages were associated
with a significantly worse prognosis (Figure 1). Both
increasing tumor cell islet macrophage density and islet/
stromal macrophage ratio also emerged as favorable inde-
pendent prognostic indicators. Stromal macrophage den-
sity was established as an independent predictor of poor
survival. Notably, 5-year survival for patients with islet
macrophage density above the median was 52.9 versus
7.7% with those below the median (p  0.0001). More-
over, similar results were evident when patients were
divided into those with a complete or incomplete surgical
resection.
Functional plasticity is a well-described characteris-
tic of macrophages of which there are at least two major
classes, referred to as M1 (“classically activated”) and M2
(“alternatively activated”) macrophages.100 While M1
macrophages elaborate proinflammatory cytokines and are
regarded as having an antitumor phenotype, M2 macro-
phages are recruited into tumors and facilitate malignant
progression through impairment of adaptive immunity.
Recently published data seem to support the hypothesis
that macrophages populating tumor islets represent a pop-
ulation that is characterized by a predominant M1 pheno-
type. Using immunohistochemistry to quantify expression
of the cytotoxic markers TNF-, HLA-DR, inducible nitric
oxide synthase, and myeloid-related protein-8/14, Ohri et
al.101 showed that patients with prolonged survival after
surgical resection show a predominance of tumor islet
macrophages characterized by an M1 phenotype compared
with those with poor survival.
Two subsequently published studies have reported
consistent findings regarding the role of inflammatory
infiltrate microlocalization, further supporting the notion
that lung cancers are invaded by at least two distinct
macrophage types. Using tissue microarray techniques,
Kim et al.102 showed that patients with a high tumor islet
macrophage density survived longer after surgical resec-
tion compared with those with low tumor islet macrophage
density, irrespective of stage (5-year survival rates, 63.9
versus 38.9%, respectively, p  0.0002). By comparison,
assessment of total macrophage count alone was not an
independent predictor of outcome. High numbers of stro-
mal macrophage were also associated with worse outcome
within the high or low tumor islet macrophage groups.
Patients with high tumor/low stromal macrophage counts
survived longest, whereas those with low tumor islet/high
stromal macrophage counts had shortest survival.
Kawai et al.66 evaluated the prognostic impact of
immune infiltrate patterns in patients with stage IV
NSCLC treated with standard platinum-based doublet che-
motherapy. These investigators similarly focused on the
FIGURE 1. Immunohistochemical staining of non-small cell lung cancer tissue sections showing the presence of CD68 mac-
rophages (red) in (A) tumor stroma and (B) tumor islets and of tryptase mast cells (brown) in (C) tumor stroma and (D) tu-
mor islets. Patients demonstrating immune cell infiltration patterns similar to panels (B) and (D) showed improved 5-year sur-
vival rates. Reprinted with permission from J Clin Oncol 2005;23:8959–8967.
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role of inflammatory cell microlocalization using tumor
biopsy specimen to study the relative distribution of mac-
rophages, mast cells, and CD8 T-cells in the different
tumor compartments. Results showed that individuals with
higher tumor islet/stroma macrophage ratio had a median
survival time more than double that of those with more
macrophages in stroma than islets. The 1-year survival
rates in the two groups were 60.8 versus 21.4%, respec-
tively. Patients with a combined high tumor islet/stroma
macrophage ratio and high tumor islet/stroma CD8T
ratio had an even greater survival advantage, and regional
distribution of both cell types emerged as favorable inde-
pendent prognostic factors. By contrast, an increased mac-
rophage infiltrate in cancer stroma conferred a significantly
worse outcome compared to low stroma macrophage
counts.
Taken together, these studies indicate that macro-
phages located in tumor islets exhibit a predominantly
antitumor phenotype, whereas those in adjacent stroma are
characterized by proangiogenic, antiapoptotic effects that
support cancer growth and dissemination. Indeed, TAMs
populating tumor islets, particularly in patients with favor-
able outcomes, seem to be distinguished by a distinct
“cytotoxic” phenotype.101 By contrast, populations within
the peritumoral stroma secrete cytokines that favor angio-
genesis and tumor progression.76 Such a hypothesis would
help account for apparent contradictory results seen in
different studies evaluating TAMs and outcome in
NSCLC.98,103
The phenotype of macrophages is critically depen-
dent on their differentiation and activation status. Using
immunostaining, Zeni et al.104 showed that the proportion
of TAMs (but not tumor cells) expressing IL-10 is in-
creased in late-stage NSCLC, was more frequently ob-
served in those with lymph node metastases, and predicts
worse overall survival. This suggests that these phagocytes
behave as M2-polarized TAMs and are complicit in neo-
plastic extension by promoting angiogenesis, tissue remod-
eling, and suppression of protective CMI responses.
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) repre-
sent a distinct population of immature myelomonocytic
cells that act as potent suppressors of host innate and
adaptive immunity. Expression of MDSCs is increased in
the setting of a variety of clinical contexts, including
bacterial and parasitic infections, autoimmunity, chemo-
therapy, and cancer.105 MDSCs that accumulate at tumor
sites represent a heterogeneous population consisting of
granulocytes, monocytes/macrophages, and dendritic cells
at various stages of differentiation that are characterized
by the expression of the common human granulocyte and
myeloid markers CD11b and CD33, respectively, but lack
CD14 or HLA markers of mature myeloid lineage cells. As
such, MDSCs do not represent a defined myeloid cell
subset, and their phenotype is critically dependent on the
tissue type they populate as well as the pattern of tumor-
derived factors elaborated.
The cardinal feature of MDSCs is potent suppression
of T-lymphocyte functionality. A number of inflammatory
mediators produced either by cancer cells or others host
immune elements that populate the tumor microenviron-
ment are believed to drive expansion of MDSC numbers
including COX2, prostaglandins, IL-1, IL-6, granulocyte
macrophage colony-stimulating factor, and vascular endo-
thelial growth factor (VEGF), among others.106,107 The
subsequent activation of MDSCs is further dependent on
several factors of which IFN-, IL-4, IL-13, and TGF-
are believed to be most important. The primary method of
MDSC-associated immunosuppression is through interfer-
ence with normal T-cell functioning via induction of the
enzymes inducible nitric oxide synthase and arginase-1. In
turn, nitration of the TCR prevents normal T-cell peptide-
MHC interactions, resulting in failure to recognize and/or
process specific tumor antigens.108 In this fashion, MDSCs
facilitate tumor immune evasion and cancer progression.
Most observations describing the immunosuppres-
sive functionality exhibited by MDSCs have thus far been
derived from animal studies, and data pertaining to the
phenotype of this population in human NSCLC are lack-
ing. Nevertheless, nearly a decade ago, Almand et al.109
identified a population of circulating CD34CD33
CD15 cells (comprising both immature macrophages and
dendritic cells) capable of suppressing antigen-specific
T-cell activity in the peripheral blood of NSCLC patients.
Accumulating evidence now suggests that MDSCs are
capable of promoting the de novo expansion of Foxp3
Tregs, thereby further contributing to the subversion of
host antitumor immunosurveillance via indirect inhibition
of effector T-cell activation and impairment of CMI.
Whether this increase in Treg numbers is the result of
conversion of Tregs from effector T lymphocytes or ex-
pansion of preexisting naturally occurring Treg numbers
remains unclear.110 The induction of Tregs is driven by
increases in IFN-, IL-10, and/or TGF-, depending on the
nature of the myeloid precursor phenotype.111 Although
these various observations indicate that crosstalk between
MDSCs and Tregs is important in contributing to CD8
T-cell anergy, it should also be noted that MDSCs are also
capable of directly suppressing effector lymphocyte activ-
ity (i.e., in the absence of regulatory lymphocyte subsets),
thereby facilitating tumor immune evasion.110
In addition to the various effects they exert on T-cell
activation, MDSCs also impair innate inflammatory cell
antitumour responses. In this regard, circulating and splen-
ic-derived MDSCs may migrate to tumor sites and through
direct cell-to-cell contact promote differentiation of mac-
rophages to an M2, alternatively activated, tumor-promot-
ing phenotype via an increase in IL-10 levels and a
concomitant decrease in macrophage-derived IL-12 levels,
further driving a predominant TH2 response that is condu-
cive to cancer cell proliferation.112 These cells also seem to
enhance tumor growth directly via additional nonimmune
mechanisms, including promotion of angiogenesis, inva-
sion, and metastasis.113
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Given their central role in immune suppression and
cancer progression, there is a strong rationale for the use of
therapeutic strategies with the potential to modulate
MDSC activity. Interestingly, gemcitabine, which is rou-
tinely used in NSCLC treatment regimens, has shown
activity against MDSCs.112 Approaches that limit MDSC
intratumoral accumulation seem to be of particular interest
in the context of cancer immunotherapy. However, the
phenotypic heterogeneity that is the hallmark of MDSCs
reduces the likelihood that the development of agents that
act on a single signaling pathway would be effective in
limiting induction of this population in cancer patients.
Furthermore, caution must be exercised when attempting
to extrapolate data derived from animal models of disease
to human lung cancer. To the best of the current authors’
knowledge, no studies specifically evaluating the clinical
relevance of tumor islet versus stroma microlocalization
with respect to MDSCs have been performed to date. As
such, to realize a therapeutic alternative that targets
MDSCs, an improved understanding of the complex inter-
actions within the tumor microenvironment between tumor
cells, MDSCs, and mature host immune populations, in
particular Tregs, is necessary.
Mast Cells
Accumulation of mast cells is characteristic of a
number of angiogenesis-dependent conditions including
arthritis,114 wound repair,115 and cancer.116–118 Mast cells
have been shown to be a significant source of the proan-
giogenic molecules VEGF, TGF-, and basic fibroblast
growth factor, and there is evidence to suggest that mast
cell infiltration may mediate angiogenesis in different
tumor types.119,120 The two major secretory products of
mast cells are chymase and tryptase.
As is the case for other inflammatory cell elements,
there are conflicting data regarding the relationship be-
tween mast cell infiltration and outcome in NSCLC, al-
though most studies have tended to show that increased
mast cell infiltration correlates with intratumoral angio-
genesis and a poor prognosis. In lung adenocarcinoma for
example, VEGF-positive tumors seem to induce intratu-
moral migration of mast cells. A strong association has
also been demonstrated between increased tryptase-posi-
tive mast cell (MCT) and tryptase- and chymase-positive
mast cell (MCTC) density and microvessel count at the
advancing tumor edge in adenocarcinoma.121 Imada et
al.122 demonstrated VEGF expression in stromal mast cells
and showed that enhanced stromal mast cell infiltrate
correlates with microvessel density in moderate-to-well
differentiated adenocarcinoma. Mast cell counts were
noted to increase as tumor stage increased. These authors
suggested that new microvessel growth may be promoted
in regions of mast cell accumulation, accounting for the
worse prognosis observed in patients after surgical resec-
tion for stage I disease.
Mast cell density was shown to correlate with in-
creased microvessel counts and was identified as an inde-
pendent predictor of poor survival among 180 patients who
underwent curative-intent surgical resection for pulmonary
adenocarcinoma.123 Tomita et al.124 also showed a strong
correlation between mast cell infiltration and angiogenesis
in both adenocarcinoma and squamous cell carcinoma.
Interestingly, these same investigators found that increased
mast cell numbers correlated with improved survival
among patients who underwent surgery for adenocarcinoma,125
and tumors characterized by higher mast cell counts were
more likely to be well differentiated. However, the precise
intratumoral distribution of mast cells in these various studies
was not reported.
It is important to note that a range of methodologies
have been used to quantify mast cells and study their
relationship to angiogenesis in NSCLC, with various cri-
teria used to define high versus low inflammatory popula-
tion infiltrates. Moreover, simple quantification of the
absolute number of tumor-associated mast cells is not
necessarily a reflection on the proportion of this population
that are functionally active.126 Perhaps crucially, patterns
of mast cell microlocalization have infrequently been re-
ported by researchers examining the prognostic relevance
of mast cells in NSCLC, a fact that may explain the
discordant results from previous studies. The importance
of this methodological consideration was highlighted in
work by Welsh et al., who evaluated surgical resection
specimens from 175 patients. These investigators showed
that a high tumor islet/stromal mast cell ratio indepen-
dently predicts favorable outcome (Figure 1).49 Patients
with total islet mast cell counts above the median had an
overall 5-year survival of 40%, compared with 22% for
those with total mast cell counts below the median value.
Thus, whether mast cells predominantly exert a pro- or
antitumor effect in NSCLC likely depends on a number of
different factors, including their precise microlocalization
within the tumor, the predominant pattern of protease
elaboration (i.e., MCT versus MCTC), and interactions with
surrounding tumor cells and other host immune elements.
SUMMARY
The precise mechanisms that underlie the different
patterns of inflammatory cell infiltration discussed in this
review remain to be more clearly elucidated. Moreover, no
standardized scheme exists to assess and quantify lym-
phoreticular infiltrates, leading to difficulties in compari-
sons between studies and the generalizability of results.
Nonetheless, continued refinements in our understanding
of the complex interplay between different components of
the host response in NSCLC are vital to identify potential
new treatment approaches for this devastating disease.
Ultimately, speculative immunomodulatory strategies that
preserve effective antitumor host immune response while
simultaneously downregulating pro-tumor inflammatory
cell populations are more likely to be translated into
successful therapies in the clinical setting in future.
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